ID: ALA1791149

Max Phase: Preclinical

Molecular Formula: C13H14N2O5S

Molecular Weight: 310.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1-c1cccs1

Standard InChI:  InChI=1S/C13H14N2O5S/c16-6-9-8(17)4-11(20-9)15-5-7(10-2-1-3-21-10)12(18)14-13(15)19/h1-3,5,8-9,11,16-17H,4,6H2,(H,14,18,19)/t8-,9+,11+/m0/s1

Standard InChI Key:  PCDQBRGMSMVLDZ-IQJOONFLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 310.33

Molecular Weight (Monoisotopic): 310.0623

AlogP: -0.09

#Rotatable Bonds: 3

Polar Surface Area: 104.55

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.54

CX Basic pKa:

CX LogP: 0.07

CX LogD: 0.06

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.73

Np Likeness Score: 0.10

References

1. Wigerinck P, Pannecouque C, Snoeck R, Claes P, De Clercq E, Herdewijn P..  (1991)  5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.,  34  (8): [PMID:1652017] [10.1021/jm00112a011]

2. De Winter H, Herdewijn P..  (1996)  Understanding the binding of 5-substituted 2'-deoxyuridine substrates to thymidine kinase of herpes simplex virus type-1.,  39  (24): [PMID:8941385] [10.1021/jm960278v]

3. Wigerinck P, Kerremans L, Claes P, Snoeck R, Maudgal P, De Clercq E, Herdewijn P..  (1993)  Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.,  36  (5): [PMID:8388474] [10.1021/jm00057a003]

Source

Source(1):

• Scientific Literature